The Spanish Ccollaborative Group for the study of Drug-Induced Liver-Injury: SPANISH DILI REGISTRY belongs to:  The Network-based biomedical research centre working on liver and digestive diseases (CIBERehd)
The Spanish Medicine Agency division of Pharmacoepidemiology & Pharmacovigilance, as a consultant group. The Red ENCePP: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance of the European Medicines Agency (EMEA). The Innovative Medicines Iniciative of the European Union for Projects: PROTECT: Strengthening the monitoring of Benefits / Risks. Collaborate in the SAFE-T project (Safer and faster evidence & in the FLIP project (Fatty Liver Inhibition of Progression) The Steering commitee of: Phenotyping Standardisation Project. Expert Working Group lead by the Prof. G Aithal y A Daly (UK) & Hepatotoxicity - Special Interest Group (SIG) collaborating with the American Association for the Study of Liver Diseases (AASLD)
|
Drug Induced Liver Injury (DILI) is due to idiosyncratic reactions not predictable from drug dosage/concentration.
These reactions place a considerable burden on health care services worldwide and pharmaceutical industry during drug development. Many common and useful drugs can cause DILI, with the precise pattern of injury varying between drugs.
Typically, DILI reactions are classified as "hepatocellular" when the injury is focused on the hepatocyte and "cholestatic" when the damage occurs at the hepatocyte canalicular membrane or further downstream in the biliary tree. The precise mechanisms of either type of reaction remain unclear; however, there is emerging evidence that both drug metabolites and immune factors play a role.
